Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Empagliflozin After Myocardial Infarction with or without diabetes and chronic kidney disease: Insights from EMPACT-MI

ESC Heart Failure(2025)10.1002/ehf2.15393Source: DataRank Database

Empagliflozin After Myocardial Infarction with or without diabetes and chronic kidney disease: Insights from EMPACT-MI is a research paper published in ESC Heart Failure (2025). On theSindex it has a DataRank of 0. It has been cited 1 time.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access1 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (2 grants)Impact (FWCI 0.68)OA: goldTopics (43)IDs (PubMed, PMC, OpenAlex)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (24)

Javed Butler ORCID,Jacob A. Udell ORCID,W. Schuyler Jones ORCID,Mark C. Petrie ORCID,Josephine Harrington

Live enrichment

PubMed:40947857 PMC:PMC12719805 OpenAlex:https://openalex.org/W4414167602

Boehringer Ingelheim and Eli Lilly and Company Diabetes Alliance

FWCI

0.68

Citation Percentile

0.7%

Citation Trend

2026

goldLicense: cc-by

journalhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ehf2.15393

publisherhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ehf2.15393

publisherhttps://academic.oup.com/eschf/article-pdf/12/6/3940/66967948/eschf_12_6_3940.pdf

journalhttps://doi.org/10.1002/ehf2.15393

repositoryhttps://pubmed.ncbi.nlm.nih.gov/40947857

Fields of Study

Diabetes Treatment and ManagementHyperglycemia and glycemic control in critically ill and hospitalized patientsPancreatic function and diabetesHumansBenzhydryl CompoundsGlucosidesMaleFemaleRenal Insufficiency, ChronicDiabetes Mellitus, Type 2Sodium-Glucose Transporter 2 InhibitorsMyocardial InfarctionAgedMiddle AgedTreatment OutcomeFollow-Up StudiesHeart FailureDouble-Blind Method

MeSH Terms

Sodium-Glucose Transporter 2 InhibitorsAgedBenzhydryl CompoundsDiabetes Mellitus, Type 2Double-Blind MethodFemaleFollow-Up StudiesGlucosidesHeart FailureHumansMaleMiddle AgedMyocardial InfarctionTreatment OutcomeRenal Insufficiency, Chronic

Keywords

EmpagliflozinMyocardial infarctionDiabetes mellitusHeart failureKidney diseaseType 2 diabetesDiabetesCkdRecommendationSglt2i